British-Swedish pharmaceutical company AstraZeneca, which is developing the AZD1222 vaccine against coronavirus, has identified a success formula that will positively affect the effectiveness of the drug. This was told in an interview with The Sunday Times AstraZeneca executive director Pascal Sorio, reports RBC.
“We think we have identified a formula for success and a way to achieve the same high performance as the rest after two doses,” said Sorio. However, he did not disclose the details of the research.
In November, the AstraZeneca vaccine was tested with two variants of administration and showed different results. The company estimated the average effectiveness of the drug at 70 percent.
There are currently several COVID-19 vaccines in the world. Thus, two vaccines are registered in Russia: Sputnik V and EpiVacCorona. On December 5, Moscow started vaccination against coronavirus with Sputnik V. The USA and Great Britain also began to inoculate the population with the drug companies Pfizer / BioNTech. In addition, the drug developed by Moderna was approved in the country. British pharmaceutical company AstraZeneca has also announced the start of clinical trials for a combination of its AZD1222 vaccine.